search
Back to results

Continuous Adductor Canal Block in Outpatient Total Knee Arthroplasty

Primary Purpose

Knee Arthroplasty, Total, Anesthesia, Regional, Acute Pain

Status
Recruiting
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Continuous adductor canal block (CACB)
Sham continuous adductor canal block (ShACB).
Sponsored by
University of Toronto
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Knee Arthroplasty, Total

Eligibility Criteria

21 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients undergoing unilateral primary TKA in the outpatient setting.
  • Patients older than 21 years of age.
  • American Society of Anesthesiologists (ASA) physical status I-III.
  • No alcohol or drug dependency.
  • Sufficient understand and co-operation about the perineural catheter.

Exclusion Criteria:

  • Perioperative complication or discharge delay leading to hospital admission.
  • Chronic opioid use of morphine 30mg equivalent per day for last 2 consecutive weeks.
  • Allergy to the study medications.
  • Coagulopathy and platelet count < 105/μL.
  • Patients with contraindications to the insertion of an epidural or adductor canal catheter (severe anatomic abnormalities or history of previous surgery at the site of catheter placement).

Sites / Locations

  • Mount Sinai HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Continuous adductor canal block (CACB)

Sham continuous adductor canal block (ShACB).

Arm Description

Will receive an infusion of 0.2% ropivacaine 5mL/h through adductor canal catheter.

Will receive an infusion of NaCl 0.9% 5mL/h through adductor canal catheter.

Outcomes

Primary Outcome Measures

Quality of Recovery 15 score (QoR-15)
Quality of Recovery 15 score (QoR-15): from 0 to 150. Higher scores mean a better outcome.

Secondary Outcome Measures

Pain scores
Numerical Rating Scale for pain (0=no pain at all; 10=worst pain)
Pain scores
Numerical Rating Scale for pain (0=no pain at all; 10=worst pain)
Pain scores
Numerical Rating Scale for pain (0=no pain at all; 10=worst pain)
Pain scores
Numerical Rating Scale for pain (0=no pain at all; 10=worst pain)
Pain scores
Numerical Rating Scale for pain (0=no pain at all; 10=worst pain)
Pain scores
Numerical Rating Scale for pain (0=no pain at all; 10=worst pain)
Opioid usage
Daily opioid usage in oral morphine equivalent doses
Opioid usage
Daily opioid usage in oral morphine equivalent doses
Opioid usage
Daily opioid usage in oral morphine equivalent doses
Opioid usage
Daily opioid usage in oral morphine equivalent doses
Opioid usage
Daily opioid usage in oral morphine equivalent doses
Opioid usage
Daily opioid usage in oral morphine equivalent doses

Full Information

First Posted
September 28, 2021
Last Updated
October 12, 2023
Sponsor
University of Toronto
Collaborators
MOUNT SINAI HOSPITAL
search

1. Study Identification

Unique Protocol Identification Number
NCT05100706
Brief Title
Continuous Adductor Canal Block in Outpatient Total Knee Arthroplasty
Official Title
Continuous Adductor Canal Block in Outpatient Total Knee Arthroplasty
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 1, 2023 (Actual)
Primary Completion Date
September 3, 2024 (Anticipated)
Study Completion Date
December 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Toronto
Collaborators
MOUNT SINAI HOSPITAL

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Total knee arthroplasty (TKA) is a frequent performed surgery. Many institutions are implementing outpatient programs for this surgery and adequate pain management is an important feature. Analgesic duration of single shot nerve blocks is limited to no more than 24h. Conversely, the use of continuous nerve block (CNB) through a perineural catheter and infusion of local anesthetic may increase duration of analgesia and provide better outcomes. The purpose of this study is to evaluate effectiveness and safety of using CNB in patients undergoing ambulatory TKA, and its effects on patients' quality of recovery. We hypothesize that continuous adductor canal block would lead to a better quality of recovery in patients undergoing outpatient TKA.
Detailed Description
Objectives: Evaluate effectiveness and safety of using continuous adductor canal block (CACB) in patients undergoing ambulatory total knee arthroplasty (TKA), in comparison to single shot adductor canal block (SACB). Primary objective is assess the quality of recovery of those patients (using the 15-item quality of recovery scale - QoR-15) at predetermined time points postoperatively. Secondary objectives are to evaluate postoperative pain scores, postoperative use of opioid, opioid-induced adverse effects (measured via validated opioid symptom distress scale), postoperative functional status, complications relating to the perineural catheter and readmissions. Hypothesis: Continuous adductor canal block would lead to a better quality of recovery in patients undergoing outpatient TKA. Methods: Randomized controlled prospective trial, blinded for patient and evaluator, in patients undergoing outpatient primary TKA at Sinai Health. After Hospital's Ethics in Research Board approval, the recruitment will begin. Patients will be assessed about their eligibility for participating and after plain clear information about the study interventions they will or will not authorize their inclusion and data collection, through the signature of a written consent. The subjects will have their surgeries booked in advance and they will be submitted to the pre anesthesia consult at the Pre Admission Unit a few days before the surgery. The study proposal will be explained to the patients in that occasion. They will receive a booklet with information about the study and the Consent Form that they will bring home with them. They will have the time between the pre anesthesia assessment and the surgery (at least two days) to review and consent to the study. Patients will be randomized to one of the two groups using a computer-generated random numbers table. The randomization will be done before the beginning of the study and will define which study number is going to be managed as interventional group (continuous adductor canal block - CACB) or control group (sham continuous adductor canal block - ShACB). Each patient will receive a study number following the order of their entrance on the study. The elastomeric pumps to be used connected to the catheter will be previously prepared by hospital pharmacy, accordingly to the randomization made and the subject study number, with no identification of the content (NaCl 0.9% or Ropivacaine 0.2%). Hospital pharmacy will not be blinded for which study number and elastomeric pump will be linked to the study group. Research coordinator, professional who performs the adductor canal catheter insertion and researcher who collects the data will be blinded to which group each patient was randomized. After accordance to participate on the study, the patient will be randomized to one of the two studies groups: continuous adductor canal block (CACB) or sham continuous adductor canal block (ShACB). All patients will receive the same perioperative management. The only difference will be the postoperative continuous perineural infusion: the CACB group will receive an infusion of 0.2% ropivacaine 5mL/h and ShACB group will receive an infusion of NaCl 0.9% 5mL/h. Patients will initially be brought to a dedicated block room where a safety checklist will be performed by the block room team. Standard Canadian Anesthesia Society monitoring will be provided. Mild sedation with Midazolam 0.5-2mg and Fentanyl 25-100mcg might be administered for anxiolysis and analgesia. After proper cleaning of the ipsilateral thigh, under sterile technique and ultrasound guidance (Sonosite Edge II ultrasound machine), an adductor canal block (injection of 15 mL of Ropivacaine 0.5% with epinephrine 1:200,000) and an IPACK block (injection of 15 mL of Ropivacaine 0.25% with epinephrine 1:200,000) will be performed. Cumulative local anesthetic doses will be preemptively calculated to avoid a total Ropivacaine dose of > 3mg/kg. After the peripheral nerve blocks, all patients will receive standard spinal or general anesthesia. All intraoperative opioids administered will be recorded. In the intra-operative period, each patient will receive IV Cefazolin 2g, Tranexamic acid 20mg/kg, Dexamethasone 0.1mg/kg, and Ondansetron 4mg. At the end of the procedure the surgeons will infiltrate the surgical site with 200 mg of Ropivacaine 0.2%. After surgery, the patient will be taken to the Post Anesthesia Care Unit. At this moment, an Arrow® (StimuCath® Continuous Peripheral Nerve Block Catheter) continuous adductor canal block catheter will be inserted using a Sonosite Edge II ultrasound machine. A bolus of 5-10mL of saline solution (NaCl 0.9%) with epinephrine 1:200,000 will be given, after negative aspiration, following adductor canal catheter insertion and the patient will be monitored for any heart rate change in order to rule out intravascular catheter placement. The catheter will be well secured with an adhesive fixation device to avoid displacement. Following catheter placement, the catheter will be aspirated to check for blood to ensure there is no intravascular placement. The catheter will be aspirated prior to any injection including at the time of saline injection during catheter placement. The peripheral nerve catheter will be connected to a Baxter elastomeric pump. Depending on which group the patient is randomized to, the solution will be Ropivacaine 0.2% or Saline 0.9%. Infusion rate will be of 5mL/h. The patient will be discharged to home after achieving the discharge criteria, keeping the peripheral nerve catheter with the same infusion rate for the planed time. The adductor canal catheter will infuse for 48 hours. Prior to going home, patients will receive education and written information (educational pamphlet) regarding monitoring for local anesthetic systemic toxicity symptoms, possible CABC associated complications including potential transient muscle weakness, and instructions on patient removal of the catheter after 48 hours. This pamphlet will contain contact information for research team or Acute Pain Service, in case of any events, adverse effects or questions the patients may have about the peripheral nerve catheter. A phone number to contact each patient at home will collected before. Standard oral analgesic scheme will be prescribed to every patient (Acetaminophen 650mg QID, Celecoxib 200mg BID, Hydromorphone 1-2mg PRN Q4Hs).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Knee Arthroplasty, Total, Anesthesia, Regional, Acute Pain

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomized controlled prospective trial, blinded for patient and evaluator, in patients undergoing outpatient primary TKA at Sinai Health.
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Patients will be randomized to one of the two groups using a computer-generated random numbers table. The randomization will be done before the beginning of the study and will define which study number is going to be managed as interventional group (continuous adductor canal block - CACB) or control group (sham continuous adductor canal block - ShACB). Each patient will receive a study number following the order of their entrance on the study. The elastomeric pumps to be used connected to the catheter will be previously prepared by hospital pharmacy, accordingly to the randomization made and the subject study number, with no identification of the content (NaCl 0.9% or Ropivacaine 0.2%). Hospital pharmacy will not be blinded for which study number and elastomeric pump will be linked to the study group. Research coordinator, professional who performs the adductor canal catheter insertion and researcher who collects the data will be blinded to which group each patient was randomized.
Allocation
Randomized
Enrollment
56 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Continuous adductor canal block (CACB)
Arm Type
Experimental
Arm Description
Will receive an infusion of 0.2% ropivacaine 5mL/h through adductor canal catheter.
Arm Title
Sham continuous adductor canal block (ShACB).
Arm Type
Placebo Comparator
Arm Description
Will receive an infusion of NaCl 0.9% 5mL/h through adductor canal catheter.
Intervention Type
Drug
Intervention Name(s)
Continuous adductor canal block (CACB)
Intervention Description
Ropivacaine 0.2% infusion through adductor canal catheter
Intervention Type
Drug
Intervention Name(s)
Sham continuous adductor canal block (ShACB).
Intervention Description
NaCl 0.9% infusion through adductor canal catheter
Primary Outcome Measure Information:
Title
Quality of Recovery 15 score (QoR-15)
Description
Quality of Recovery 15 score (QoR-15): from 0 to 150. Higher scores mean a better outcome.
Time Frame
Day 3
Secondary Outcome Measure Information:
Title
Pain scores
Description
Numerical Rating Scale for pain (0=no pain at all; 10=worst pain)
Time Frame
Day 1
Title
Pain scores
Description
Numerical Rating Scale for pain (0=no pain at all; 10=worst pain)
Time Frame
Day 2
Title
Pain scores
Description
Numerical Rating Scale for pain (0=no pain at all; 10=worst pain)
Time Frame
Day 3
Title
Pain scores
Description
Numerical Rating Scale for pain (0=no pain at all; 10=worst pain)
Time Frame
Day 7
Title
Pain scores
Description
Numerical Rating Scale for pain (0=no pain at all; 10=worst pain)
Time Frame
Day 30
Title
Pain scores
Description
Numerical Rating Scale for pain (0=no pain at all; 10=worst pain)
Time Frame
Day 90
Title
Opioid usage
Description
Daily opioid usage in oral morphine equivalent doses
Time Frame
Day 1
Title
Opioid usage
Description
Daily opioid usage in oral morphine equivalent doses
Time Frame
Day 2
Title
Opioid usage
Description
Daily opioid usage in oral morphine equivalent doses
Time Frame
Day 3
Title
Opioid usage
Description
Daily opioid usage in oral morphine equivalent doses
Time Frame
Day 7
Title
Opioid usage
Description
Daily opioid usage in oral morphine equivalent doses
Time Frame
Day 30
Title
Opioid usage
Description
Daily opioid usage in oral morphine equivalent doses
Time Frame
Day 90

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients undergoing unilateral primary TKA in the outpatient setting. Patients older than 21 years of age. American Society of Anesthesiologists (ASA) physical status I-III. No alcohol or drug dependency. Sufficient understand and co-operation about the perineural catheter. Exclusion Criteria: Perioperative complication or discharge delay leading to hospital admission. Chronic opioid use of morphine 30mg equivalent per day for last 2 consecutive weeks. Allergy to the study medications. Coagulopathy and platelet count < 105/μL. Patients with contraindications to the insertion of an epidural or adductor canal catheter (severe anatomic abnormalities or history of previous surgery at the site of catheter placement).
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Hermann dos Santos Fernandes, MD, PhD
Phone
+1 647 568 8292
Email
hermannfernandes@yahoo.com.br
First Name & Middle Initial & Last Name or Official Title & Degree
Yehoshua Gleicher, MD, MSc
Phone
+1 416 875 4533
Email
Josh.Gleicher@sinaihealth.ca
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Naveed Siddiqui, MD, MSc
Organizational Affiliation
University of Toronto
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mount Sinai Hospital
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G 1X5
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hermann dos Santos Fernandes, MD, PhD
Phone
+1 647 568 8292
Email
hermann.dossantosfernandes@sinaihealth.ca
First Name & Middle Initial & Last Name & Degree
Yehoshua Gleicher, MD, MSc
Phone
+1 416 875-4533
Email
josh.gleicher@sinaihealth.ca

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
30496082
Citation
Price AJ, Alvand A, Troelsen A, Katz JN, Hooper G, Gray A, Carr A, Beard D. Knee replacement. Lancet. 2018 Nov 3;392(10158):1672-1682. doi: 10.1016/S0140-6736(18)32344-4.
Results Reference
background
PubMed Identifier
28283810
Citation
Cullom C, Weed JT. Anesthetic and Analgesic Management for Outpatient Knee Arthroplasty. Curr Pain Headache Rep. 2017 May;21(5):23. doi: 10.1007/s11916-017-0623-y.
Results Reference
background
PubMed Identifier
20889937
Citation
Ilfeld BM, Duke KB, Donohue MC. The association between lower extremity continuous peripheral nerve blocks and patient falls after knee and hip arthroplasty. Anesth Analg. 2010 Dec;111(6):1552-4. doi: 10.1213/ANE.0b013e3181fb9507. Epub 2010 Oct 1.
Results Reference
background
PubMed Identifier
19680735
Citation
Sharma S, Iorio R, Specht LM, Davies-Lepie S, Healy WL. Complications of femoral nerve block for total knee arthroplasty. Clin Orthop Relat Res. 2010 Jan;468(1):135-40. doi: 10.1007/s11999-009-1025-1. Epub 2009 Aug 13.
Results Reference
background
PubMed Identifier
29721648
Citation
Sankineani SR, Reddy ARC, Eachempati KK, Jangale A, Gurava Reddy AV. Comparison of adductor canal block and IPACK block (interspace between the popliteal artery and the capsule of the posterior knee) with adductor canal block alone after total knee arthroplasty: a prospective control trial on pain and knee function in immediate postoperative period. Eur J Orthop Surg Traumatol. 2018 Oct;28(7):1391-1395. doi: 10.1007/s00590-018-2218-7. Epub 2018 May 2.
Results Reference
background
PubMed Identifier
29890381
Citation
Leung P, Dickerson DM, Denduluri SK, Mohammed MK, Lu M, Anitescu M, Luu HH. Postoperative continuous adductor canal block for total knee arthroplasty improves pain and functional recovery: A randomized controlled clinical trial. J Clin Anesth. 2018 Sep;49:46-52. doi: 10.1016/j.jclinane.2018.06.004. Epub 2018 Jun 8.
Results Reference
background
PubMed Identifier
33120783
Citation
Yu R, Wang H, Zhuo Y, Liu D, Wu C, Zhang Y. Continuous adductor canal block provides better performance after total knee arthroplasty compared with the single-shot adductor canal block?: An updated meta-analysis of randomized controlled trials. Medicine (Baltimore). 2020 Oct 23;99(43):e22762. doi: 10.1097/MD.0000000000022762.
Results Reference
background
PubMed Identifier
27871518
Citation
Hanson NA, Lee PH, Yuan SC, Choi DS, Allen CJ, Auyong DB. Continuous ambulatory adductor canal catheters for patients undergoing knee arthroplasty surgery. J Clin Anesth. 2016 Dec;35:190-194. doi: 10.1016/j.jclinane.2016.07.022. Epub 2016 Aug 30.
Results Reference
background
PubMed Identifier
31903564
Citation
Myles PS. More than just morbidity and mortality - quality of recovery and long-term functional recovery after surgery. Anaesthesia. 2020 Jan;75 Suppl 1:e143-e150. doi: 10.1111/anae.14786.
Results Reference
background
PubMed Identifier
32443383
Citation
Sun C, Zhang X, Song F, Zhao Z, Du R, Wu S, Ma Q, Cai X. Is continuous catheter adductor canal block better than single-shot canal adductor canal block in primary total knee arthroplasty?: A GRADE analysis of the evidence through a systematic review and meta-analysis. Medicine (Baltimore). 2020 May;99(20):e20320. doi: 10.1097/MD.0000000000020320.
Results Reference
background
PubMed Identifier
27264877
Citation
Johansson Stark A, Charalambous A, Istomina N, Salantera S, Sigurdardottir AK, Sourtzi P, Valkeapaa K, Zabalegui A, Bachrach-Lindstrom M. The quality of recovery on discharge from hospital, a comparison between patients undergoing hip and knee replacement - a European study. J Clin Nurs. 2016 Sep;25(17-18):2489-501. doi: 10.1111/jocn.13278. Epub 2016 Jun 6.
Results Reference
background

Learn more about this trial

Continuous Adductor Canal Block in Outpatient Total Knee Arthroplasty

We'll reach out to this number within 24 hrs